| 產(chǎn)品名稱 | LY 2784544 - Gandotinib |
| 產(chǎn)品貨號(hào) | Axon 2554 CAS [1229236-86-5] MF C23H25ClFN7OMW 469.94 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Potent, selective and ATP-competitive inhibitor of janus kinase 2 (JAK2) tyrosine kinase (IC50 value 20 and 55?nM for inhibition of JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells, respectively), with no significant inhibitory effect on IL-3 stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50 values >1180 nM) A selective tool for suppression of JAK2V617F-induced myeloproliferative neoplasm (MPN) pathogenesis while minimizing effects on hematopoietic progenitor cells. Moreover, LY2784544 induced apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway; tested positive in Phase I study in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). KEYWORDS: LY 2784544 | supplier | JAK2 Inhibitor | Gandotinib | LY2784544 |CAS [1229236-86-5] | JAK-STATPathway | JAK | Inhibitor | janus kinase | tyrosine kinase | ATP competitive | JAK2V617F | proliferation | ?myeloproliferative neoplasm | MNP | apoptosis | inflammatory | myelofibrosis (MF) | polycythemia vera (PV) | essential thrombocythemia (ET) |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
LY 2784544 - GandotinibAxon 2554 CAS [1229236-86-5] MF C23H25ClFN7O
DescriptionPotent, selective and ATP-competitive inhibitor of janus kinase 2 (JAK2) tyrosine kinase (IC50 value 20 and 55?nM for inhibition of JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells, respectively), with no significant inhibitory effect on IL-3 stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50 values >1180 nM) A selective tool for suppression of JAK2V617F-induced myeloproliferative neoplasm (MPN) pathogenesis while minimizing effects on hematopoietic progenitor cells. Moreover, LY2784544 induced apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway; tested positive in Phase I study in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). KEYWORDS: LY 2784544 | supplier | JAK2 Inhibitor | Gandotinib | LY2784544 |CAS [1229236-86-5] | JAK-STATPathway | JAK | Inhibitor | janus kinase | tyrosine kinase | ATP competitive | JAK2V617F | proliferation | ?myeloproliferative neoplasm | MNP | apoptosis | inflammatory | myelofibrosis (MF) | polycythemia vera (PV) | essential thrombocythemia (ET)
Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F)
Chemical name3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine Parent CAS No.[1229236-86-5] |
| 產(chǎn)品資料 |
